These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37008582)

  • 61. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
    Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
    Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
    Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
    Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.
    Michallet M; Gangneux JP; Lafuma A; Herbrecht R; Ribaud P; Caillot D; Dupont B; Moreau P; Berger P; O'Sullivan AK
    J Med Econ; 2011; 14(1):28-35. PubMed ID: 21175376
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
    Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
    Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.
    Calmettes C; Gabriel F; Blanchard E; Servant V; Bouchet S; Kabore N; Forcade E; Leroyer C; Bidet A; Latrabe V; Leguay T; Vigouroux S; Tabrizi R; Breilh D; Accoceberry I; de Lara MT; Pigneux A; Milpied N; Dumas PY
    Oncotarget; 2018 Jun; 9(42):26724-26736. PubMed ID: 29928481
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis.
    Sezgin Evim M; Tüfekçi Ö; Baytan B; Ören H; Çelebi S; Ener B; Üstün Elmas K; Yılmaz Ş; Erdem M; Hacımustafaoğlu MK; Güneş AM
    Turk J Haematol; 2022 Jun; 39(2):94-102. PubMed ID: 34792308
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia.
    Shah A; Ganesan P; Radhakrishnan V; Kannan K; Rajendranath R; Mahajan V; Vijayakumar V; Ganesan T; Sagar TG
    Indian J Med Paediatr Oncol; 2016; 37(1):53-8. PubMed ID: 27051159
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study.
    Chen X; Wang J; Wang S; Jin J; Li J; Gao S; Li J; Li J; Liu Q; Hu Y; Lin D; Sun Z; Yang J; Hu J; Wu X; Huang X; Shao Z; Deng Q; Wang C; Liu L; Chen H; Wang J; Wei X; Shen J; Zhang X; Wu D
    Medicine (Baltimore); 2021 Jul; 100(30):e26772. PubMed ID: 34397725
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia.
    Le Clech L; Uguen M; Quinio D; Nevez G; Couturier MA; Ianotto JC; Berthou C; Guillerm G; Le Bars H; Payan C; Narbonne V; Baron R; Saliou P
    Curr Res Transl Med; 2020 Jan; 68(1):23-28. PubMed ID: 31787568
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
    Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
    JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland.
    Greiner RA; Meier Y; Papadopoulos G; O'Sullivan AK; Imhof A
    Oncology; 2010; 78(3-4):172-80. PubMed ID: 20414005
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.
    Girmenia C; Frustaci AM; Gentile G; Minotti C; Cartoni C; Capria S; Trisolini SM; Matturro A; Loglisci G; Latagliata R; Breccia M; Meloni G; Alimena G; Foà R; Micozzi A
    Haematologica; 2012 Apr; 97(4):560-7. PubMed ID: 22102706
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Voriconazole prophylaxis in leukemic patients: A retrospective single-center study.
    Bui V; Walker SA; Elligsen M; Vyas A; Kiss A; Palmay L
    J Oncol Pharm Pract; 2020 Jun; 26(4):873-881. PubMed ID: 31566111
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
    Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
    J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting.
    Berking S; Doedens D; Horns H; Fiegl M; Ostermann H; Rieger CT
    Mycoses; 2017 Sep; 60(9):600-606. PubMed ID: 28504318
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
    de la Cámara R; Jarque I; Sanz MA; Grau S; Casado MA; Sabater FJ; Carreras E
    Bone Marrow Transplant; 2010 May; 45(5):925-32. PubMed ID: 19802030
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation.
    Linder KA; Kauffman CA; Patel TS; Fitzgerald LJ; Richards BJ; Miceli MH
    Transpl Infect Dis; 2021 Feb; 23(1):e13448. PubMed ID: 33448560
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?
    Chen TC; Wang RC; Lin YH; Chang KH; Hung LY; Teng CJ
    Ther Adv Hematol; 2020; 11():2040620720965846. PubMed ID: 33194163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.